IRLAB Therapeutics Ownership
IRLAB Therapeutics AB has a total of 51.79 Million outstanding shares. IRLAB Therapeutics secures noticeable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as IRLAB Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of IRLAB Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
IRLAB |
IRLAB Stock Ownership Analysis
About 39.0% of the company shares are held by company insiders. The company had not issued any dividends in recent years. IRLAB Therapeutics had 5:1 split on the 28th of May 2019. IRLAB Therapeutics AB operates as a drug discovery and development company that provides drugs in the field of neurological and neuropsychiatric disorders. Its pipeline candidates include IRL790, a psychomotor stabilizer for the treatment of L-dopa induced dyskinesias in Parkinsons disease and Parkinson disease psychosis IRL752, a cortical enhancer for the treatment of Parkinson disease dementia and behavioral and psychological symptoms of dementia IRL626, a fast-off D2 antagonist for use in the treatment of schizophrenia P001, a cortical enhancer program for the treatment of attention disorders and IRL448IRL555, a followup Parkinsons disease program. IRLAB Therapeutics is traded on Stockholm Stock Exchange in Sweden. To learn more about IRLAB Therapeutics AB call the company at 46 3 17 57 38 00 or check out https://www.irlab.se.IRLAB Therapeutics Outstanding Bonds
IRLAB Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. IRLAB Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most IRLAB bonds can be classified according to their maturity, which is the date when IRLAB Therapeutics AB has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in IRLAB Stock
IRLAB Therapeutics financial ratios help investors to determine whether IRLAB Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in IRLAB with respect to the benefits of owning IRLAB Therapeutics security.